Atrogi Announces Positive Clinical Data from First-in-Class Insulin-Independent Treatment for Type 2 Diabetes
Atrogi, a pioneering clinical-stage biotech company advancing treatments for metabolic disorders, announces the full set of results from its Phase 1 a/b trial with ATR-258, its first-in-class treatment for type 2 diabetes (T2D). This clinical trial, conducted on both healthy…
Sigrid Therapeutics Launches the Glucose Stabiliser in the U.S.
Sigrid Therapeutics has launched the Glucose Stabiliser, an over-the-counter blood sugar control supplement that also reduces caloric intake from fats and carbs. With about 1 in every 10 Americans facing a Type 2 diagnosis and the growing popularity of medications used for…
